
News|Articles|December 1, 2012
Early therapy with basal insulin does not reduce cardiovascular outcomes in dysglycemic patients
Early initiation of basal insulin did not impact cardiovascular outcomes compared to standard management of glucose in patients with type 2 diabetes or elevated fasting glucose with cardiovascular risk factors.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
Myqorzo is now available for rare heart condition at a $108,400 annual price
3
When it comes to quality measures, fewer is viewed as better, says Ben Shirley of PQA | Part 2
4
Could GLP-1s help with cognitive symptoms, pychosis of schizophrenia?
5























